# Radiology Pathology Case Presentation

Tyler Lescure MS4 January 17<sup>th</sup>, 2020



SCHOOL of MEDICINE




- 1. Introduction to the case
- 2. Timeline of events
- 3. CT scan diagnosis of current concern
- 4. Pathology results
- 5. CT-guided biopsy
- 6. Prognosis

#### Case

A 53-year-old man with a history of chronic hepatitis C, alcohol abuse, porphyria cutaneous tarda, and chronic sinusitis presents with a new liver lesion concerning for hepatocellular carcinoma.

- 1. 2002 developed skin lesions diagnosed as porphyria cutaneous tarda (PCT)
  - a. ~70% of cases of PCT are caused by Hep C
  - b. Per pt report, tested positive for Hep C at that time
  - c. Lost to follow-up. His HCV was left untreated



- 2. December 2012 Presents to GI for HCV treatment
  - a. Risk factors for HCV:
    - i. Blood transfusions (1989)
    - ii. IVDA (1980s)
    - iii. Tattoos (1980s)
  - b. Repeat labs confirmed infection with a high viral load
  - c. Liver biopsy performed: mild fat, grade 2 inflammation, stage 2 to focal stage 3 fibrosis d/t HCV1




Additional social history:

- Started smoking 1 ppd around age 23 (30 pack year history)
- Long alcohol use history
  - 6-9 beers on weeknights, 12 beers on weekends
  - Attempted to quit at this time but unsuccessful




3. October 2019 – developed right sided abdominal pain, weight loss, N/V. OSH MRI revealed large necrotic right hepatic lobe tumor suspected to be hepatocellular carcinoma (HCC)




OSH MRI Results:


- Hepatic steatosis with an infiltrative, enhancing 10 cm mass in the right hepatic lobe suggestive of combined hepatocellular-cholangiocarcinoma. Tumor infiltrating right posterior portal vein and right hepatic vein.
- LR-M, TIV
  - LR-M: liver lesions probably malignant but appearance not compatible with HCC
  - LR-TIV: invasion of the portal vein (contraindication to liver transplant)




#### OSH MRI Results:



- 4. 12/12/19 Referred to IR for further work-up and treatment
  - Ablation not at option d/t tumor size (optimal for tumors < 3 cm)
  - Transarterial chemoembolization (TACE) not safe due to occlusion of right posterior portal vein and right hepatic vein
  - Surgery not precluded as no evidence of extra-hepatic disease
  - Staging CT ordered




- 5. Chest CT done 12/16/2019:
- Multiple (~40) subcentimeter pulmonary nodules, consistent with metastatic disease
- No lymphadenopathy or osseous lesions




Chest CT (12/16/2019)









- 6. 12/30/2019 Consultation with transplant surgery
- Discussed with patient that though the tumor is technically resectable, would only make sense if cancer was limited to the liver
- Recommended biopsy of lung nodules to rule out metastasis




- 7. 1/15/2020 CT guided lung biopsy
  - Imaging revealed overall increase in size and number of pulmonary nodules
  - Left lower lobe pulmonary nodules targeted:




- 7. 1/15/2020 CT guided lung biopsy
  - 22-guage FNA was performed:
    - Cells were obtained but definitive diagnosis difficult due to excessive blood
    - Sample insufficient for definitive diagnosis




#### Example FNA of metastatic carcinoma to the lung



- 7. 1/15/2020 CT guided lung biopsy
  - 22-guage FNA was performed:
    - · Cells were obtained but definitive diagnosis difficult due to excessive blood
    - Sample insufficient for definitive diagnosis
  - 3 core biopsies obtained, results pending
  - Blood patch used to seal entry site




#### Post-procedural Chest X ray:



# Prognosis

- Prognosis of HCC is poor, due to high recurrence and rapid metastasis
- 34.5% of pts with HCC have mets to the lung
- 1-year survival for patients with extrahepatic mets is only about 25%
- Overall 5-year survival for HCC is 10%



Thank you